Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230030/S018

FARAPULSE Pulsed Field Ablation System

Farapulse, Inc. · Decision date Aug 6, 2026

FDA DECISIONP230030/S018

What did the FDA approve?

FDA records P230030/S018 as a supplement to PMA P230030, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 6, 2026.

FDA approval order statement

approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P230030/S012.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Aug 6, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P230030/S018
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Aug 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P230030. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230030 · Original PMA

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

  2. P230030/S015 · Related supplement

    FARAPULSE Pulsed Field Ablation System

  3. P230030/S014 · Related supplement

    FARAPULSE Pulsed Field Ablation System

  4. P230030/S013 · Related supplement

    FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul

  5. P230030/S012 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARAWAVE NAV Pulsed Field Ablation C

  6. P230030/S017 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAPULSE)

  7. P230030/S018 received

    Application receipt date recorded by FDA.

  8. P230030/S019 · Related supplement

    FARAPULSE Pulsed Field Ablation System

  9. P230030/S021 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

  10. P230030/S023 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

  11. P230030/S022 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAPULSE)

  12. P230030/S018 · FDA decision

    Normal 180 Day Track No User Fee

  13. P230030/S016 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

  14. P230030/S024 · Related supplement

    FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul

  15. P230030/S025 · Related supplement

    FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,

Timeline entries are records held by MedtechLedger for P230030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230030

Product / regulatory recordCompanyPathwayDecision dateSource
Farapulse, Inc.PMA approvalJan 30, 2024FDA
Farapulse, Inc.PMA supplementAug 12, 2025FDA
Farapulse, Inc.PMA supplementAug 14, 2025FDA
Farapulse, Inc.PMA supplementSep 24, 2025FDA
Farapulse, Inc.PMA supplementJan 12, 2026FDA
Farapulse, Inc.PMA supplementJan 13, 2026FDA
Farapulse, Inc.PMA supplementMay 6, 2026FDA
Farapulse, Inc.PMA supplementJun 5, 2026FDA
Farapulse, Inc.PMA supplementJun 26, 2026FDA
Farapulse, Inc.PMA supplementJul 10, 2026FDA
Farapulse, Inc.PMA supplementAug 25, 2026FDA
Farapulse, Inc.PMA supplementSep 4, 2026FDA
Farapulse, Inc.PMA supplementOct 2, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Farapulse, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3715 Haven Ave., Suite 110, Menlo Park, CA, 94025

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records